NASDAQ:GLTO Galecto (GLTO) Stock Price, News & Analysis → If you have $2,500 bucks… check this out (From DTI) (Ad) Free GLTO Stock Alerts $0.70 +0.04 (+6.02%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.65▼$0.7150-Day Range$0.66▼$0.8952-Week Range$0.50▼$3.70Volume119,427 shsAverage Volume120,048 shsMarket Capitalization$19.11 millionP/E RatioN/ADividend YieldN/APrice Target$5.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Galecto alerts: Email Address Galecto MarketRank™ Stock AnalysisAnalyst RatingHold2.20 Rating ScoreUpside/Downside656.7% Upside$5.33 Price TargetShort InterestHealthy0.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.50Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.59) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.42 out of 5 starsMedical Sector476th out of 914 stocksPharmaceutical Preparations Industry203rd out of 418 stocks 3.1 Analyst's Opinion Consensus RatingGalecto has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageGalecto has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.09% of the float of Galecto has been sold short.Short Interest Ratio / Days to CoverGalecto has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galecto has recently decreased by 42.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldGalecto does not currently pay a dividend.Dividend GrowthGalecto does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GLTO. Previous Next 2.5 News and Social Media Coverage News SentimentGalecto has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Galecto this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for GLTO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Galecto to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Galecto insiders have not sold or bought any company stock.Percentage Held by Insiders12.10% of the stock of Galecto is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 14.20% of the stock of Galecto is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Galecto are expected to decrease in the coming year, from ($1.59) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Galecto is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galecto is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalecto has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad TranzactWhat is Medicare Supplement Insurance?Original Medicare helps covers a lot of hospital and medical services, but it still leaves some out- of- pocket medical costs to recipients. Make sure your family’s nest egg is protected from unpredictable medical expenses. Consider applying for a Medicare Supplement Insurance Plan that travels with you. Learn More Here About Galecto Stock (NASDAQ:GLTO)Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Read More GLTO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GLTO Stock News HeadlinesApril 22, 2024 | theglobeandmail.com6 Stocks Positioned to Soar as Investors Focus on MASHApril 18, 2024 | americanbankingnews.comGalecto (NASDAQ:GLTO) Shares Down 1.9% April 27, 2024 | Prosper Trading Academy (Ad)These AI trades triggered this morning (545% return)If you think a market crash is possible in 2024, I don't know why you're not using this yet.March 15, 2024 | msn.comGLTO Stock Earnings: Galecto Beats EPS for Q4 2023February 16, 2024 | thestreet.comGalecto Inc.February 14, 2024 | finance.yahoo.comGalecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?January 9, 2024 | finance.yahoo.comWhat Makes Galecto, Inc. (GLTO) a New Strong Buy StockDecember 23, 2023 | finanznachrichten.deGalecto, Inc.: Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisApril 27, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. December 22, 2023 | msn.comNike, AAR And 3 Stocks To Watch Heading Into FridayDecember 21, 2023 | finance.yahoo.comTopline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with MyelofibrosisOctober 23, 2023 | finance.yahoo.comGalecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 TrialOctober 5, 2023 | msn.comGalecto (GLTO) Price Target Increased by 13.16% to 5.48October 2, 2023 | finanznachrichten.deGalecto, Inc.: Galecto Announces Plans to Explore Strategic AlternativesSeptember 30, 2023 | msn.comHC Wainwright & Co. Downgrades Galecto (GLTO)September 27, 2023 | bizjournals.comWeeks after dropping lung disease drug, Galecto lays off most of staff, explores saleSeptember 26, 2023 | finance.yahoo.comGalecto Announces Plans to Explore Strategic AlternativesSeptember 14, 2023 | msn.comGalecto Biotech Collapse: Opportunity For Galectin TherapeuticsAugust 31, 2023 | finance.yahoo.comGalecto to Present at Investor Conferences in SeptemberAugust 22, 2023 | msn.comHC Wainwright & Co. Maintains Galecto (GLTO) Buy RecommendationAugust 21, 2023 | markets.businessinsider.comExpert Ratings for GalectoAugust 17, 2023 | finance.yahoo.comBiotech Stock Roundup: GLTO Plunges on Setback, BLUE Offers Updates & MoreAugust 16, 2023 | marketwatch.comGalecto Ends Development of Lead Candidate After IPF Study Failure >GLTOAugust 16, 2023 | finance.yahoo.comGalecto (GLTO) Down 71% as Lung Disease Candidate FailsAugust 15, 2023 | msn.comSVB Leerink Downgrades Galecto (GLTO)August 15, 2023 | bizjournals.comGalecto shares plummet after biotech drops lung disease drugAugust 15, 2023 | msn.comWhy Is Galecto Stock Plummeting Today?See More Headlines Receive GLTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galecto and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/08/2024Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLTO CUSIPN/A CIK1800315 Webgalecto.com Phone45-7070-5210FaxN/AEmployees13Year FoundedN/APrice Target and Rating Average Stock Price Target$5.33 High Stock Price Target$12.00 Low Stock Price Target$2.00 Potential Upside/Downside+656.7%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,350,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-93.68% Return on Assets-72.46% Debt Debt-to-Equity RatioN/A Current Ratio6.31 Quick Ratio6.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.19 per share Price / Book0.59Miscellaneous Outstanding Shares27,110,000Free Float23,832,000Market Cap$19.11 million OptionableOptionable Beta1.24 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Hans T. Schambye M.D. (Age 58)Ph.D., Co-Founder, President, CEO & Director Comp: $700.13kMr. Jonathan P. Freve CPA (Age 46)CPA, Chief Financial Officer Comp: $604.93kMr. Ulf J. NilssonCo-FounderDr. Hakon LefflerCo-FounderProf. Tariq Sethi B.Sc.FRCP, M.A., M.D., Ph.D., Co-FounderMr. Garrett Winslow Esq. (Age 45)Senior VP, General Counsel & Corporate Secretary More ExecutivesKey CompetitorsAlaunos TherapeuticsNASDAQ:TCRTFlora GrowthNASDAQ:FLGCNeuroSense TherapeuticsNASDAQ:NRSNBioVieNASDAQ:BIVIAptorum GroupNASDAQ:APMView All CompetitorsInsidersOrbimed Advisors LlcSold 209,400 sharesTotal: $628,200.00 ($3.00/share)Orbimed Advisors LlcSold 39,200 sharesTotal: $114,464.00 ($2.92/share)Orbimed Advisors LlcSold 194,700 sharesTotal: $467,280.00 ($2.40/share)View All Insider Transactions GLTO Stock Analysis - Frequently Asked Questions Should I buy or sell Galecto stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Galecto in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GLTO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GLTO, but not buy additional shares or sell existing shares. View GLTO analyst ratings or view top-rated stocks. What is Galecto's stock price target for 2024? 5 Wall Street analysts have issued 12 month target prices for Galecto's shares. Their GLTO share price targets range from $2.00 to $12.00. On average, they anticipate the company's share price to reach $5.33 in the next year. This suggests a possible upside of 656.7% from the stock's current price. View analysts price targets for GLTO or view top-rated stocks among Wall Street analysts. How have GLTO shares performed in 2024? Galecto's stock was trading at $0.72 on January 1st, 2024. Since then, GLTO stock has decreased by 2.1% and is now trading at $0.7048. View the best growth stocks for 2024 here. Are investors shorting Galecto? Galecto saw a decline in short interest in April. As of April 15th, there was short interest totaling 18,000 shares, a decline of 42.9% from the March 31st total of 31,500 shares. Based on an average daily trading volume, of 221,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.1% of the shares of the stock are sold short. View Galecto's Short Interest. How were Galecto's earnings last quarter? Galecto, Inc. (NASDAQ:GLTO) released its earnings results on Friday, March, 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.31) by $0.08. When did Galecto IPO? Galecto (GLTO) raised $86 million in an initial public offering (IPO) on Thursday, October 29th 2020. The company issued 5,700,000 shares at a price of $14.00-$16.00 per share. BofA Securities, SVB Leerink and Credit Suisse acted as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Galecto? Shares of GLTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GLTO) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galecto, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
